S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
LON:SLN

Silence Therapeutics (SLN) Share Price, News & Analysis

GBX 535
-5.00 (-0.93%)
(As of 11/29/2021)
Today's Range
512
546
50-Day Range
535
535
52-Week Range
411
680
Volume
913,528 shs
Average Volume
80,100 shs
Market Capitalization
£480.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
SLN stock logo

About Silence Therapeutics Stock (LON:SLN)

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase Ib clinical trials for the treatment of myelodysplastic syndrome; and SLN500 for the treatment of complement-mediated diseases. It has a collaboration agreements with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.

SLN Stock Price History

SLN Stock News Headlines

Major Elon Musk Crypto Leak Revealed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
Is Silence Golden for This Small-Cap Biotech Stock?
Grab Your Free Bitcoin Today!
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
Silence Therapeutics PLC ADR SLN
Where Silence Therapeutics Stands With Analysts
Silence Therapeutics Plc (NASDAQ: SLN)
The Latest Analyst Ratings for Silence Therapeutics
See More Headlines
Receive SLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Silence Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
9/14/2020
Today
3/29/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
74
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£11.35 million
Cash Flow
GBX 84.41 per share
Book Value
GBX 18.20 per share

Miscellaneous

Free Float
N/A
Market Cap
£480.35 million
Optionable
Not Optionable
Beta
N/A
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Mark Andrew Rothera (Age 58)
    Pres, CEO & Exec. Director
    Comp: $521.23k
  • Dr. Giles V. Campion M.D. (Age 67)
    Exec. VP, Head of R&D, Chief Medical Officer and Exec. Director
    Comp: $436.2k
  • Mr. Craig A. Tooman M.B.A. (Age 55)
    MBA, Chief Financial Officer
  • Ms. Gem Gokmen Hopkins
    Head of IR & Corp. Communications
  • Dr. Barbara A. Ruskin (Age 61)
    Sr. VP, Gen. Counsel & Chief Patent Officer
  • Ms. Linnea Elrington
    VP & Head of HR
  • Dr. John Strafford
    VP & Head of Bus. Devel.
  • Mr. Jørgen Wittendorff
    Sr. VP & Head of Manufacturing
  • Dr. Marie Wikstrom Lindholm Ph.D.
    Sr. VP & Head of Molecular Design

SLN Stock Analysis - Frequently Asked Questions

How have SLN shares performed in 2024?

Silence Therapeutics' stock was trading at GBX 535 on January 1st, 2024. Since then, SLN shares have increased by 0.0% and is now trading at GBX 535.
View the best growth stocks for 2024 here
.

How were Silence Therapeutics' earnings last quarter?

Silence Therapeutics plc (LON:SLN) announced its quarterly earnings results on Monday, September, 14th. The company reported ($13.70) EPS for the quarter, topping analysts' consensus estimates of ($21.70) by $8.00.

What other stocks do shareholders of Silence Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Silence Therapeutics investors own include Arch Therapeutics (ARTH), QuickLogic (QUIK), Asiamet Resources (ARS), ArcBest (ARCB), American Renal Associates (ARA), Apergy (APY), Anchiano Therapeutics (ANCN), Aileron Therapeutics (ALRN), Alkermes (ALKS) and Alfa Financial Software (ALFA).

How do I buy shares of Silence Therapeutics?

Shares of SLN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:SLN) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners